Ignalis-M 50/500 Tablet ER is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients whose hyperglycemia is inadequately controlled by diet and exercise alone. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Ignalis-M 50/500 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic control is recommended during therapy. This combination therapy offers a synergistic approach to glycemic control by targeting multiple pathophysiological defects in type 2 diabetes.